Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06441994
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2024-05-26
Brief Title:
Clinical Trial of Targeted Alpha Therapy Using At-211PSMA-5 for Prostate Cancer
Sponsor:
Osaka University
Organization:
Osaka University
Study Overview
Official Title:
A Phase I Investigator-initiated Clinical Trial of a Novel Targeted Alpha Therapy Using At-211PSMA-5 for Patients With Castration-resistant Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Alpha-PS1
Brief Summary:
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability safety pharmacokinetics absorbed dose and efficacy as well as to determine the recommended dose for Phase II
Detailed Description:
PSW-1025 is administered intravenously to patients with castration-resistant prostate cancer to evaluate its tolerability safety pharmacokinetics absorbed dose and efficacy as well as to determine the recommended dose for Phase II PSW-1025 At-211PSMA-5 is an alpha-ray-emitting drug labeled with Astatine At-211 that targets PSMA Prostate Specific Membrane Antigen
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None